Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice

Japanese Journal of Cancer Research

Volumn 89, Issue 4, 1998, Pages 392-396

  Quesada, Carlos F ^a   Kimata, Hiroyuki ^a   Mori, Masayuki ^a   Nishimura, Masahiko ^a   Tsuneyoshi, Toshihiro ^b   Baba, Shozo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Acarbose; APC 1309 knockout mice; Chemoprevention; Intestinal adenoma; Piroxicam

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; COLON CARCINOMA; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL POLYPOSIS; GASTROINTESTINAL TRACT; INTESTINE CANCER; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0031979329     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00576.x     Document Type: Article

References (36)

1. Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Stolley, P. D. and Shapiro, S. A. Hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J. Natl. Cancer Inst., 83, 355-358 (1991).
2. Thun, M. J., Namboodiri, M. M. and Heath, C.W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325, 1593-1596 (1991).
3. DuBois, R. N., Giardello, F. M. and Smalley, W. E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am., 25, 773-791 (1996).
4. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V. and Reddy, B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55, 1464-1472 (1995).
5. Moser, A. R., Dove, W. F., Roth, K. A. and Gordon, J. L. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J. Cell Biol., 116, 1517-1526 (1992).
6. Jacoby, R. F., Marshall, D. J., Newton, M. A., Novakovic, K., Tutsh, K., Cole, C. E., Lubet, R. A., Kellof, G. J., Verma, A., Moser, A. R. and Dove, W. F. Chemoprevention of spontaneous intestinal adenomas in the Apc min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 56, 710-714 (1996).
7. Rigas, B., Goldman, I. S. and Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122, 518-523 (1993).
8. Williams, C. W. and Dubois, R. N. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol., 270, 6393-6400 (1996).
9. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwang, E., Trzaskos, J. M., Evans, J. and Taketo, M. M. Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell, 87, 803-09 (1996).
10. Dubois, R. N., Radhika, A., Reddy, B. S. and Entingh, A. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology, 110, 1259-1262 (1996).
11. Cybulsky, A. V., Goodyer, P. R., Cyr, M. D. and McTavish, A. J. Eicosanoids enhance epidermal growth factor receptor activation and proliferation in glomerular epithelial cells. Am. J. Physiol., 262, 639-646 (1992).
12. Denizot, Y., Najid, A. and Rigaud, M. Effects of eicosanoid metabolism inhibitors on growth of a human gastric tumor cell line (HGT). Cancer Lett., 73, 65-71 (1993).
13. Shapiro, A. C., Wu, D. and Meydani, S. N. Eicosanoids derived from arachidonic and eicosapentaenoic acids inhibit T cell proliferative response. Prostaglandins, 45, 229-240 (1993).
14. Shiff, S. J., Qiao, L., Tsai, L. L. and Rigas, B. Sulindac sulfide, an aspirin like compound, inhibits proliferation, causes cell cycle quiescence and induces apoplosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest., 96, 491-503 (1995).
15. Lombardino, J. G. and Wiseman, E. H. Piroxicam and other anti-inflammatory oxicams. Med. Res. Rev., 2, 127-152 (1982).
16. Pollard, M. and Luckert, P. H. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J. Natl. Cancer Inst., 70, 1103-1105 (1983).
17. Holt, P. R., Atillasoy, E., Lindenbaum, J., Ho, S. B., Lupton, J. R., MacMahon, D. and Moss, S. F. Effects of acarbose on fecal nutrients, colonic pH. and short-chain fatty acids and rectal proliferative indices. Metabolism, 45, 1179-1187 (1996).
18. Thornton, J. R. High colonic pH promotes colorectal cancer. Lancet, i, 1081-1082 (1981).
19. Ito, M., Miura, S. and Noda, T. Mouse model for familial adenomatous polyposis coli and APC gene. Protein Nucl. Acid Enzyme, 40, 2035-2044 (1995) (in Japanese).
20. Ito, M., Shibata, H. and Noda, T. Mouse model for human cancer predisposition. Med. Today, 51, 1153-1160 (1996) (in Japanese).
21. Groden, J., Thliveris, A. and Samoritz, W. Identification and characterization of the familial adenomatous polyposis. Cell, 66, 589-600 (1991).
22. Kinzler, K. W., Nilbert, M. C. and Su, L. K. Identification of FAP locus genes from chromosome 5q21. Science, 253, 661-665 (1991).
23. Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., Volgenstein, B. and Kinsler, K. W. APC mutations occur early during colorectal tumorigenesis. Nature, 359, 235-237 (1992).
24. Giardello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R. and Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328, 1313-1316 (1993).
25. Nicholls, R. J., Springall, R. G. and Gallagher, P. Regression of rectal adenomas after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Br. Med. J., 296, 1707-1708 (1988).
26. Moser, A. L., Pitot, H. C. and Dove, W. F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 247, 322-324 (1990).
27. Vane, J. R. Towards a better aspirin. Nature, 367, 215-216 (1994).
28. Eberhart, C. H., Coffey, R. J., Radhika, A., Giardello, F., Ferrenbach, S. and Dubois, R. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-1188 (1994).
29. Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. B., Beauchamp, R. D. and Dubois, R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 110, 1259-1262 (1996).
30. Morris, P. and Phyllis, H. L. Prevention and treatment of primary intestinal tumor in rats by piroxicam. Cancer Res., 49, 6471-6473 (1989).
31. Su, L. K., Kinzler, K. W., Volgenstein, B., Preisinger, A. C., Mosser, A. R., Luongo, C., Gould, K. A. and Dove, W. F. Multiple intestinal neoplasia caused by a mutation in the murine homologue of the APC gene. Science, 256, 668-670 (1992).
32. Prosad, K. N. Butyric acid, a small fatty acid with diverse biological functions. Life Sci., 27, 1351-1358 (1980).
33. Van Munster, I. P. and Nagengast, F. M. The role of carbohydrate fermentation in colon cancer prevention. Scand. J. Gastroenterol., 200, 80-86 (1993).
34. Lupton, J. and Kurtz, P. Relationship of colonic luminal short-chain fatty acids and pH to in vivo cell proliferation in rats. J. Nutr., 123, 1522-1530 (1993).
35. Sakata, T. Stimulatory effect of short-chain fatty acids on epithelial cells of the rat colon. Gastroenterology, 83, 425-429 (1987).
36. Bradburn, D. M., Mathers, J. C., Gunn, A., Burn, J., Chapman P. D., and Johnston, I. D. A. Colonic fermentation of complex carbohydrates in patients with familial adenomatous polyposis. Gut, 34, 630-636 (1993).